May 8, 2023

Dublin, IRELAND Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This "Checkpoint inhibitors - Competitive landscape, 2023" report provides comprehensive insights about 180+ companies and 250+ drugs in Checkpoint inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights In April 2023, Enlivex Therapeutics Ltd. announced a clinical collaboration agreement with BeiGene. The Company entered into this collaboration to evaluate the safety and efficacy of AllocetraT, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumors, a part of the Company's ongoing Phase I/II clinical trial. In January 2023, CARsgen Therapeutics Holdings Limited had announced CARsgen's execution of a collaboration agreement with F. Hoffmann-La Roche Ltd to evaluate CARsgen's investigational drug AB011, the first humanized monoclonal antibody against Claudin18.2 (CLDN18.2) that received IND clearance globally, in combination with atezolizumab, Roche's PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with gastric or gastroesophageal junction carcinoma . Under the terms of the agreement, Roche will be responsible for operation and conduct of the trial while both companies co-share the costs of the AB011 treatment arms in the study. In January 2023, Teon Therapeutics, announced that it has entered into the clinical trial collaboration agreement with Merck. The agreement is for the combination arm of Teon's ongoing, two-armed, open-label, dose escalation and expansion clinical study and will evaluate Teon's oral, immune response modifier, TT-816, in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for patients with advanced solid tumors. In October 2022, Immune-Onc Therapeutics, Inc. ("Immune-Onc"), announced it has entered into a clinical trial collaboration and supply agreement with BeiGene to evaluate Immune-Onc's first-in-class myeloid checkpoint inhibitors, IO-108 and IO-202, in combination with BeiGene's anti-PD-1 antibody, tislelizumab, as part of its clinical development programs in China. In October 2022, Exelixis, Inc. announced the expansion of its June 2021 Clinical Trial Collaboration and Supply Agreement with Bristol-Myers Squibb Company to include the use of the fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial (NCT05176483), which is evaluating XL092 in combination with multiple immune checkpoint inhibitors (ICIs) in advanced solid tumors. Current Treatment Scenario and Emerging Therapies: How many companies are developing Checkpoint inhibitors drugs? How many Checkpoint inhibitors drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Checkpoint inhibitors? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Checkpoint inhibitors therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Checkpoint inhibitors and their status? What are the key designations that have been granted to the emerging and approved drugs? Key Players